Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients
Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find out if IL-11 (NeumegaTM) may increase the
platelet count in patients with Chronic myeloid leukemia (CML) who develop low platelet
counts while receiving therapy with imatinib mesylate (Gleevec, STI571), or other tyrosine
kinase inhibitors such as AMN107, dasatinib, or SK1606.
Primary Objective:
1. To determine efficacy of low-dose interleukin-11, (IL-11, oprelvekin, NeumegaTM) in
improving the thrombocytopenia associate with imatinib or other tyrosine kinase inhibitor
therapy in patients with CML.
Secondary Objective:
1. To determine the safety of low-dose IL-11 in patients with CML and thrombocytopenia
associated with imatinib or other tyrosine kinase inhibitors